Document Detail

Critical evaluation of the efficacy and tolerability of azilsartan.
MedLine Citation:
PMID:  22661897     Owner:  NLM     Status:  MEDLINE    
Appropriate control of blood pressure (BP) in hypertensive patients still represents the major therapeutic goal in the treatment of hypertension. Despite the growing attention and wide range of antihypertensive agents available in the clinical scenario, the target of BP below the advised thresholds of 140/90 mmHg is, unfortunately, often unreached. For this reason, the search for new antihypertensive agents is still ongoing. Azilsartan medoxomil, a new angiotensin receptor blocker that has been recently introduced in the clinical arena, represents the eighth angiotensin receptor blocker currently available for BP control. The aim of this paper is to describe the efficacy and safety profile of this new compound, reviewing available data obtained from both pre-clinical and clinical studies.
Alberto R De Caterina; Andrew R Harper; Florim Cuculi
Related Documents :
15481767 - Association of anthropometric indices with elevated blood pressure in british adults.
11206677 - Sleep effects on ambulatory blood pressure measurements in pregnant women.
11494087 - Menopause and the characteristics of the large arteries in a population study.
18814997 - Postpartum preeclampsia: emergency department presentation and management.
3521337 - Control of sodium excretion by angiotensin ii: intrarenal mechanisms and blood pressure...
11835757 - Effect of mild hypothermia on partial pressure of oxygen in brain tissue and brain temp...
Publication Detail:
Type:  Journal Article; Review     Date:  2012-05-14
Journal Detail:
Title:  Vascular health and risk management     Volume:  8     ISSN:  1178-2048     ISO Abbreviation:  Vasc Health Risk Manag     Publication Date:  2012  
Date Detail:
Created Date:  2012-06-04     Completed Date:  2012-09-04     Revised Date:  2013-07-12    
Medline Journal Info:
Nlm Unique ID:  101273479     Medline TA:  Vasc Health Risk Manag     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  299-305     Citation Subset:  IM    
Istituto Scienze della Vita, Scuola Superiore Sant'Anna, Pisa, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II Type 1 Receptor Blockers / adverse effects,  pharmacokinetics,  therapeutic use*
Antihypertensive Agents / adverse effects,  pharmacokinetics,  therapeutic use*
Benzimidazoles / adverse effects,  pharmacokinetics,  therapeutic use*
Blood Pressure / drug effects*
Drug Interactions
Evidence-Based Medicine
Hypertension / drug therapy*,  physiopathology
Oxadiazoles / adverse effects,  pharmacokinetics,  therapeutic use*
Renin-Angiotensin System / drug effects
Risk Assessment
Treatment Outcome
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 0/Benzimidazoles; 0/Oxadiazoles; 0/azilsartan medoxomil; F9NUX55P23/azilsartan
Erratum In:
Vasc Health Risk Manag. 2012;8:443-5

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Smoking status and sex as indicators of differences in 2582 obese patients presenting for weight man...
Next Document:  Use of carvedilol in hypertension: an update.